Hostname: page-component-8448b6f56d-jr42d Total loading time: 0 Render date: 2024-04-24T17:48:57.058Z Has data issue: false hasContentIssue false
  • English
  • Français

Hexafluorodiethyl Ether (Indoklon) Convulsive Therapy: A Pilot Study

Published online by Cambridge University Press:  29 January 2018

D. R. Gander ,
P. J. Bennett  and
D. H. W. Kelly
D. R. Gander
Affiliation:
Queen Elizabeth II Hospital, Welwyn Garden City, Hertfordshire
P. J. Bennett
Affiliation:
Department of Anaesthetics, St. Thomas's Hospital, London, S.E.1
D. H. W. Kelly
Affiliation:
Department of Psychological Medicine, St. Thomas's Hospital, London, S.E.1
Get access Rights & Permissions [Opens in a new window]

Extract

In 1957 Krantz, Truitt, Ling and Speers found that the inhalation of small amounts of hexafluorodiethyl ether (Indoklon) produced convulsions in animals, and it was later used as a therapeutic convulsant for the treatment of psychiatric patients (Krantz, Truitt, Speers and Ling, 1957).

Type
Research Article
Information
The British Journal of Psychiatry , Volume 113 , Issue 505 , December 1967 , pp. 1413 - 1418
Copyright
Copyright © Royal College of Psychiatrists, 1967 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Esquibel, A. J., Krantz, J. C., Truitt, E. B., Ling, A. S. C., and Kurland, A. A. (1958). “Hexafluorodiethyl ether (Indoklon): its use as a convulsant in psychiatric treatment.” J. nerv. ment. Dis., 126, 530–534.CrossRefGoogle Scholar
Karliner, W. (1965). “Observations on the use of bis (2,2,2, trifluoroethyl) ether.” Int. J. Neuropsychiat., 1, 139–143.Google Scholar
Karliner, W. and Padula, L. J. (1960). “The use of hexafluorodiethyl ether in psychiatric treatment.” J. Neuropsychiat., 2, 67–70.Google Scholar
Krantz, J. C., Esquibel, A., Truitt, E. B., Ling, A. S. C., and Kurland, A. A. (1958). “Hexafluorodiethyl ether (Indoklon): an inhalant convulsant: its use in psychiatric treatment.” J. Amer. med. Assn., 166, 1555–1562.Google Scholar
Krantz, J. C., and Truitt, E. B. (1959). “The pharmacologic and therapeutic properties of hexafluorodiethyl ether (Indoklon).” Honoris Causa Volume for Prof. G. Joachimoglu, Athens.Google Scholar
Krantz, J. C., Truitt, E. B., Ling, A. S. C., and Speers, L. (1957). “Anaesthesia, LV. The pharmacologic response to hexafluorodiethyl ether.” J. Pharmacol. and Exper. Therap., 121, 362–368.Google Scholar
Krantz, J. C., Truitt, E. B., Speers, L., and Ling, A. S. C. (1957). “New pharmaco-convulsive agent.” Science, 126, 353–354.Google Scholar
Kurland, A. A. (1963). “Implications of Indoklon for psychiatric research.” J. Neuropsychiat., 4, 173–177.Google Scholar
Nussbaum, K., and Kurland, A. A. (1962). “Intravenous hexafluorodiethyl ether (Indoklon) modified by succinylcholine chloride. Clinical studies in convulsive psychiatric treatment.” Curr. Ther. Res., 4, 44–56.Google Scholar
Padula, L. J., and Karliner, W. (1963). “Inhalation Indoklon convulsive therapy.” J. Neuropsychiat., 4, 182–183.Google Scholar
Rosenberg, I. D. (1962). “Resistant psychosis treated successfully by Indoklon (1, 2, 3).” Amer. J. Psychiat., 118, 1050–1051.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.